Your browser doesn't support javascript.
loading
Different Mutational Profiles of Subcutaneous Panniculitis-like T-cell Lymphoma and Lupus Panniculitis: An Additional Case Series.
Machan, S; Rodríguez, M; Manso, R; Borregón, J; Chamizo, C; Alonso-Alonso, R; Rodríguez-Peralto, J L; Torres Nieto, M Á; Monteagudo, C; García Toro, E; Cerroni, L; García, C; Estrach, T; García Herrera, A; Ferrer, B; García-Patos, V; Segues, N; Díaz de la Pinta, F J; Afonso-Martin, J L; Peñate, Y; Limeres-Gonzalez, M Á; González-Núñez, M Á; González-Cruz, C; García Fernández, E; Cereceda, L; Minguez, P; de la Fuente, L; Requena, L; Rodríguez-Pinilla, S M.
Afiliación
  • Machan S; Department of Dermatology, Fundación Jiménez Díaz-IIS, Universidad Autónoma de Madrid, Madrid, Spain.
  • Rodríguez M; Department of Pathology, Fundación Jiménez Díaz-IIS, Universidad Autónoma de Madrid, Madrid, Spain; CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Spain.
  • Manso R; Department of Pathology, Fundación Jiménez Díaz-IIS, Universidad Autónoma de Madrid, Madrid, Spain; CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Spain. Electronic address: rebeca.manso@quironsalud.es.
  • Borregón J; Department of Pathology, Fundación Jiménez Díaz-IIS, Universidad Autónoma de Madrid, Madrid, Spain; CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Spain.
  • Chamizo C; Department of Pathology, Fundación Jiménez Díaz-IIS, Universidad Autónoma de Madrid, Madrid, Spain; CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Spain.
  • Alonso-Alonso R; Department of Pathology, Fundación Jiménez Díaz-IIS, Universidad Autónoma de Madrid, Madrid, Spain; CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Spain.
  • Rodríguez-Peralto JL; Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Torres Nieto MÁ; Hospital Universitario Río Hortega, Valladolid, Spain.
  • Monteagudo C; Hospital Clínico Universitario de Valencia, Universidad de Valencia, Valencia, Spain.
  • García Toro E; Hospital Universitario de Burgos, Burgos, Spain.
  • Cerroni L; Dermatopathology Research Unit, Department of Dermatology, Medical University of Graz, Graz, Austria.
  • García C; Hospital Universitario de Canarias, Tenerife, Spain.
  • Estrach T; Hospital Clínic de Barcelona, Barcelona, Spain.
  • García Herrera A; Hospital Clínic de Barcelona, Barcelona, Spain.
  • Ferrer B; Hospital Vall d'Hebron, Barcelona, Spain.
  • García-Patos V; Hospital Vall d'Hebron, Barcelona, Spain.
  • Segues N; Hospital Universitario Donostia, San Sebastián, Spain.
  • Díaz de la Pinta FJ; Department of Pathology, Fundación Jiménez Díaz-IIS, Universidad Autónoma de Madrid, Madrid, Spain; CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Spain.
  • Afonso-Martin JL; Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain.
  • Peñate Y; Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain.
  • Limeres-Gonzalez MÁ; Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain.
  • González-Núñez MÁ; Hospital Ciudad de Coria y Hospital San Pedro de Alcántara, Cáceres, Spain.
  • González-Cruz C; Hospital Vall d'Hebron, Barcelona, Spain.
  • García Fernández E; Department of Hematology, Fundación Jiménez Díaz-IIS, Universidad Autónoma de Madrid, Madrid, Spain.
  • Cereceda L; Department of Pathology, Fundación Jiménez Díaz-IIS, Universidad Autónoma de Madrid, Madrid, Spain; CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Spain.
  • Minguez P; Department of Genetics, Instituto de Investigación Sanitaria - Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain; Bioinformatics Unit, Instituto de Investigación Sanitaria - Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Mad
  • de la Fuente L; Department of Genetics, Instituto de Investigación Sanitaria - Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain; Bioinformatics Unit, Instituto de Investigación Sanitaria - Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Mad
  • Requena L; Department of Dermatology, Fundación Jiménez Díaz-IIS, Universidad Autónoma de Madrid, Madrid, Spain.
  • Rodríguez-Pinilla SM; Department of Pathology, Fundación Jiménez Díaz-IIS, Universidad Autónoma de Madrid, Madrid, Spain; CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Spain.
Actas Dermosifiliogr ; 2024 Jul 18.
Article en En, Es | MEDLINE | ID: mdl-39032781
ABSTRACT

BACKGROUND:

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare cytotoxic T-cell lymphoma with indolent behavior, mostly present in women and associated with immunological diseases whose pathogenic background is still poorly understood. SPTCL is associated with lupus erythematosus panniculitis (LEP) and histologically misdiagnosed.

OBJECTIVES:

The aim of our study was to identify mutations affecting the pathogenesis of both SPTCL and LEP. MATERIALS AND

METHODS:

We studied a total of 10 SPTCL and 10 LEP patients using targeted next-generation sequencing and pyrosequencing. Differences in gene expression between molecular subgroups were investigated using NanoString technology. Clinical data were collected, and correlations sought with the molecular data obtained.

RESULTS:

The mutational profile of SPTCL and LEP is different. We identified fewer pathogenic mutations than previously reported in SPTCL, noting a single HAVCR2-mutated SPTCL case. Interestingly, 40% of our SPTCL cases showed the pathogenic TP53 (p.Pro72Arg) (P72R) variant. Although cases showing HAVCR2 mutations or the TP53 (P72R) variant had more severe symptomatic disease, none developed hemophagocytic syndrome (HPS). Furthermore, TP53 (P72R)-positive cases were characterized by a lower metabolic signaling pathway and higher levels of CD28 expression and Treg signaling genes. In addition, 30% of our cases featured the same mutation (T735C) of the epigenetic modificatory gene DNMT3A. None of the LEP cases showed mutations in any of the studied genes.

CONCLUSIONS:

The mutational landscape of SPTCL is broader than previously anticipated. We describe, for the first time, the involvement of the TP53 (P72R) pathogenic variant in this subgroup of tumors, consider the possible role of different genetic backgrounds in the development of SPTCL, and conclude that LEP does not follow the same pathogenic pathway as SPTCL.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En / Es Revista: Actas Dermosifiliogr Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: España

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En / Es Revista: Actas Dermosifiliogr Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: España